Polyrizon Ltd. Announces Positive Pre-Clinical Results for PL-14 Allergy Blocker, Paving Way for Clinical Trials
Reuters
Oct 06
<a href="https://laohu8.com/S/PLRZ">Polyrizon Ltd.</a> Announces Positive Pre-Clinical Results for PL-14 Allergy Blocker, Paving Way for Clinical Trials
Polyrizon Ltd. has announced positive results from a recent pre-clinical study evaluating its PL-14 Allergy Blocker, developed using the company's proprietary Capture & Contain (C&C) platform. The study assessed the formulation's ability to create a hydrogel barrier that limits the penetration of Der p 1, a major house dust mite allergen. Results showed that PL-14 significantly restricted allergen diffusion, with only 1.07% passing through after one hour, 1.14% after two hours, and 13.6% after four hours. The allergen concentrations used in the study were substantially higher than typical real-world exposures. The company plans to initiate clinical studies to further support regulatory and clinical development of PL-14 and other candidates within the C&C platform. The pre-clinical results have already been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9540580-en) on October 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.